Serial Number:
79295795
Mark:
ITM MEDICAL ISOTOPES
Status:
Registered
Status Date:
06-15-2021
Filing Date:
Registration Number:
6383043
Registration Date:
06-15-2021
Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnosis purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes Conducting clinical trials for others at all stages and in various indications, particularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET] Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology
Mark Description:
The mark consists of "ITM MEDICAL ISOTOPES" in stylized form with two circles emanating from the left corner of the "I" in "ITM" at a diagonal.
Class:
Medical services
Type of Mark:
Trademark
Published for Opposition Date:
03-30-2021
Mark Drawing Status:
Design plus Words, Letters, and/or Numbers
Abandon Date:
N/A
Business Name:
LEWIS KOHN & WALKER LLP
Correspondent Name:
